Safety of Biologics and Small Molecules for Inflammatory Bowel Diseases in Organ Transplant Recipients
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: This study aimed to evaluate the safety of biologics and small molecules for the treatment of inflammatory bowel diseases (IBD) in patients receiving antirejection therapies after organ transplants. Materials and Methods: We reviewed the medical records of patients with IBD who received organ transplants at the Asan Medical Center between January 1989 and December 2021. We compared the parameters of patients receiving biologics or small molecules to those of patients without those therapies. Results: This study included a total of 53 patients (ulcerative colitis, 41; Crohn’s disease, 6; and gastrointestinal Behçet’s disease, 6). Among them, 15 patients were receiving biologics or small molecules and 38 were not. During a mean follow-up of 119 months, the proportion of patients experiencing severe infections was significantly higher in those treated with biologics or small molecules than in those not treated. However, other safety outcomes (e.g., malignancies, adverse events, including organizing pneumonia or hepatic failure, and death) were not different between the two groups. Kaplan–Meier curve analysis revealed no significant difference in the safety outcome rate related to the use of biologics or small molecules. During follow-up, eight patients underwent bowel resections for IBD. The rate of bowel resection was not different between the two groups. Conclusion: The use of biologics or small molecules for patients with IBD who received organ transplants did not show a significant difference in safety outcomes. However, the possibility of severe infections must be considered.
Abstract
Purpose: This study aimed to evaluate the safety of biologics and small molecules for the treatment of inflammatory bowel diseases (IBD) in patients receiving antirejection therapies after organ transplants. Materials and Methods: We reviewed the medical records of patients with IBD who received organ transplants at the Asan Medical Center between January 1989 and December 2021. We compared the parameters of patients receiving biologics or small molecules to those of patients without those therapies. Results: This study included a total of 53 patients (ulcerative colitis, 41; Crohn’s disease, 6; and gastrointestinal Behçet’s disease, 6). Among them, 15 patients were receiving biologics or small molecules and 38 were not. During a mean follow-up of 119 months, the proportion of patients experiencing severe infections was significantly higher in those treated with biologics or small molecules than in those not treated. However, other safety outcomes (e.g., malignancies, adverse events, including organizing pneumonia or hepatic failure, and death) were not different between the two groups. Kaplan–Meier curve analysis revealed no significant difference in the safety outcome rate related to the use of biologics or small molecules. During follow-up, eight patients underwent bowel resections for IBD. The rate of bowel resection was not different between the two groups. Conclusion: The use of biologics or small molecules for patients with IBD who received organ transplants did not show a significant difference in safety outcomes. However, the possibility of severe infections must be considered.
참고문헌 (31)
- Gizard E, "Systematic review : the epidemiology of the hepatobiliary manifestations in patients with inflammatory bowel disease", Aliment Pharmacol Ther, 40, pp.3~15 (2014)
- Oikonomou K, "Renal manifestations and complications of inflammatory bowel disease", Inflamm Bowel Dis, 17, pp.1034~1045 (2011)
- Rust C, "PSC : protect and serve with colitis : does it help the liver to have severe ulcerative colitis?", Gut, 60, pp.1165~1166 (2011)
- Singh S, "Inflammatory bowel disease after liver transplantation for primary sclerosing cholangitis", Am J Gastroenterol, 108, pp.1417~1425 (2013)
- Weng MT, "Association of young age and male sex with primary sclerosing cholangitis in Taiwanese patients with inflammatory bowel disease", Intest Res, 20, pp.224~230 (2022)
- Hayashi R, "Clinical characteristics of inflammatory bowel disease patients with immunoglobulin A nephropathy", Intest Res, 19, pp.430~437 (2021)
- Gheith O, "Erythema nodosum in renal transplant recipients : multiple cases and review of literature", Transpl Infect Dis, 12, pp.164~168 (2010)
- Temme J, "Infliximab as therapeutic option in steroid-refractory ulcerative colitis after kidney transplantation : case report", Transplant Proc, 42, pp.3880~3882 (2010)
- Parameswaran S, "Ulcerative colitis after renal transplantation : a case report and review of literature", Indian J Nephrol, 21, pp.120~122 (2011)
- Azevedo P, "A case series of de novo inflammatory bowel disease after kidney transplantation", Transplant Proc, 45, pp.1084~1087 (2013)
- Rutgeerts P, "Infliximab for induction and maintenance therapy for ulcerative colitis", N Engl J Med, 353, pp.2462~2476 (2005)
- Colombel JF, "The safety of vedolizumab for ulcerative colitis and Crohn's disease", Gut, 66, pp.839~851 (2017)
- Sandborn WJ, "Tofacitinib as induction and maintenance therapy for ulcerative colitis", N Engl J Med, 376, pp.1723~1736 (2017)
- Feuerstein JD, "AGA clinical practice guidelines on the medical management of moderate to severe luminal and perianal fistulizing Crohn’s disease", Gastroenterology, 160, pp.2496~2508 (2021)
- van Hoek B, "Risk factors for infection after liver transplantation", Best Pract Res Clin Gastroenterol, 26, pp.61~72 (2012)
- Daniel KE, "Why do patients die after a liver transplantation?", Clin Transplant, 31, pp.e12906~ (2017)
- Koh SJ, "Korean clinical practice guidelines on biologics for moderate to severe Crohn’s disease", Intest Res, 21, pp.43~60 (2023)
- Lewis JD, "Use of the noninvasive components of the Mayo score to assess clinical response in ulcerative colitis", Inflamm Bowel Dis, 14, pp.1660~1666 (2008)
- Turner D, "A systematic prospective comparison of noninvasive disease activity indices in ulcerative colitis", Clin Gastroenterol Hepatol, 7, pp.1081~1088 (2009)
- Lee HJ, "Optimal diagnosis and disease activity monitoring of intestinal Behçet’s disease", Intest Res, 15, pp.311~317 (2017)
- Burroughs AK, "3-month and 12-month mortality after first liver transplant in adults in Europe : predictive models for outcome", Lancet, 367, pp.225~232 (2006)
- Fishman JA, "Infection in organ-transplant recipients", N Engl J Med, 338, pp.1741~1751 (1998)
- Westerouen van Meeteren MJ, "Safety of anti-TNF treatment in liver transplant recipients : a systematic review and metaanalysis", J Crohns Colitis, 11, pp.1146~1151 (2017)
- Taneja V, "Safety of biologic and small molecule therapy for inflammatory bowel disease among solid organ transplant recipients : systematic review and meta-analysis", Inflamm Bowel Dis (2023)[DOI]
- Ribaldone DG, "Non-hepatic solid organ transplant in patients with inflammatory bowel disease : an ECCO CONFER multicentre case series", J Crohns Colitis, 17, pp.1097~1102 (2023)
- Singh JA, "Adverse effects of biologics : a network meta-analysis and Cochrane overview", Cochrane Database Syst Rev, 2011, pp.CD008794~ (2011)
- Schreiber S, "Systematic review with meta-analysis : real-world effectiveness and safety of vedolizumab in patients with inflammatory bowel disease", J Gastroenterol, 53, pp.1048~1064 (2018)
- Mao EJ, "Systematic review with meta-analysis : comparative efficacy of immunosuppressants and biologics for reducing hospitalisation and surgery in Crohn’s disease and ulcerative colitis", Aliment Pharmacol Ther, 45, pp.3~13 (2017)
- Dvorchik I, "Effect of liver transplantation on inflammatory bowel disease in patients with primary sclerosing cholangitis", Hepatology, 35, pp.380~384 (2002)
- Verdonk RC, "Inflammatory bowel disease after liver transplantation : risk factors for recurrence and de novo disease", Am J Transplant, 6, pp.1422~1429 (2006)
- Matsuoka K, "Incidence rates for hospitalized infections, herpes zoster, and malignancies in patients with ulcerative colitis in Japan : an administrative health claims database analysis", Intest Res, 21, pp.88~99 (2023)